Awards

The IMOR Foundation,Medical Institute for Radiation Oncology has been awarded the Judith Stitt Award considered the highest honour in the world, by the (American brachytherapy Society) for its outstanding contribution to the conservative treatment of prostate cancer and the continuous improvementof the quality of life of patients. . The award was presented in Toronto to Professor Benjamín Guix, who gave a conference entitled Treatment of intermediate or high risk prostate cancer using intensity modulated radiation therapy (IMRT) and brachytherapy.

“One of the advantages of intraoperative radiotherapy is that it prevents any remaining tumour cells from proliferating when the wound is healing”.

Doctor Benjamín Guix director of the IMOR Foundation, speaks to Vanguardia Salud about the advantages of intraoperative radiotherapy for breast cancer.



Download File


Prostate brachytherapy is effective in almost 100% of cases.

Early diagnosis improves prognosis and treatment is more effective and with fewer side effects.



Download File

Brachytherapy, better than surgery in prostate cancer.

A Spanish study published in the International Journal of Radiation Oncology-Biology-Physics which included the participation of the IMOR Foundation, Medical Institute for RadiationOncology in Barcelona, concluded that patients with low-risk localised prostate cancer maintain a better quality of life when treated with brachytherapy than with surgery or radiotherapy alone, and that brachytherapy combined with IMRT offers a better quality of life to patients with localised intermediate or high-risk prostate cancer.


Download File

"We have achieved spectacular outcomes in prostate cancer"

In an interview in Periódico Universal, Doctor Benjamín Guix, director of the IMOR Foundation, Medical Institute for Radiation Oncology in Barcelona, explained the advances in radiation therapy and brachytherapy that now make it possible to cure the vast majority of patients with tumours.



Download File





Elderly patients with prostate cancer who are treated actively show much better progress than those who adopt expectant behaviour or not very efficient treatments. The article describes how patients over 75 treated actively (with brachytherapy or radiation therapy) for prostate cancer instead of follow-up of the progression of the disease, have a risk of dying from any cause of only a third that of patients who receive no treatment.

logos mutuas imor
logos mutuas imor
logos mutuas imor
logos mutuas imor